We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pharma Stock Roundup: AZN's Small Cancer Firm Buyout, FDA Updates for PFE, RHHBY
Read MoreHide Full Article
This week, the FDA granted priority review status to Roche’s (RHHBY - Free Report) regulatory application for lymphoma candidate, Lunsumio. AstraZeneca (AZN - Free Report) announced a small acquisition that will strengthen its hematological cancer pipeline. Pfizer (PFE - Free Report) filed a new drug application (NDA) to the FDA for its oral COVID-19 pill, Paxlovid, which was until now authorized for emergency use in the United States.
Recap of the Week’s Most Important Stories
AstraZeneca’s New Acquisition to Strengthen Hematological Cancer Pipeline: AstraZeneca announced that it has agreed to acquire TeneoTwo and its early-stage CD19/CD3 T-cell engager, TNB-486, which will strengthen its hematological cancer pipeline. TNB-486 is currently being evaluated in a phase I study in relapsed and refractory B-cell non-Hodgkin lymphoma1. Per the terms of the agreement, AstraZeneca will make an upfront payment of $100 million upon the closure of the deal. In addition to the upfront payment, the existing shareholders of TeneoTwo will also be eligible to receive contingent R&D-related milestone payments of up to $805 million and additional contingent commercial-related milestone payments of up to $360 million.
FDA’s Priority Tag to Roche’s Lymphoma Candidate BLA: The FDA accepted and granted priority review to Roche’s biologics license application (BLA) for Lunsumio, to treat adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior systemic therapies. Lunsumio is a potential first-in-classCD20xCD3 T-cell engaging bispecific antibody. The FDA is expected to give its decision on the BLA by Dec 29, 2022. The BLA is based on positive results from the pivotal phase I/II GO29781 study.
Pfizer Files NDA for Paxlovid: Pfizer announced that it has filed a new drug application (NDA) to seek formal approval from the FDA for its oral COVID-19 antiviral pill, Paxlovid. Paxlovid was granted Emergency Use Authorization (EUA) in the United States in December 2021 for the treatment of mild-to-moderate COVID-19 in patients who are at high risk of progression to severe COVID-19. The NDA seeks approval of Paxlovid for patients who are at high risk for progression to severe illness from COVID-19. The NDA was based on data from the phase II/III EPIC-HR study. Paxlovid has already received emergency or conditional authorization for use in certain populations in more than 65 countries.
The NYSE ARCA Pharmaceutical Index rose 0.63% in the last five trading sessions.
Here’s how the eight major stocks performed in the last five trading sessions.
Image Source: Zacks Investment Research
In the last five trading sessions, Merck rose the most (2%) while AbbVie declined the most (0.8%).
In the past six months, Lilly rose the most (26.1%) while Roche declined the most (17.5%).
Image: Bigstock
Pharma Stock Roundup: AZN's Small Cancer Firm Buyout, FDA Updates for PFE, RHHBY
This week, the FDA granted priority review status to Roche’s (RHHBY - Free Report) regulatory application for lymphoma candidate, Lunsumio. AstraZeneca (AZN - Free Report) announced a small acquisition that will strengthen its hematological cancer pipeline. Pfizer (PFE - Free Report) filed a new drug application (NDA) to the FDA for its oral COVID-19 pill, Paxlovid, which was until now authorized for emergency use in the United States.
Recap of the Week’s Most Important Stories
AstraZeneca’s New Acquisition to Strengthen Hematological Cancer Pipeline: AstraZeneca announced that it has agreed to acquire TeneoTwo and its early-stage CD19/CD3 T-cell engager, TNB-486, which will strengthen its hematological cancer pipeline. TNB-486 is currently being evaluated in a phase I study in relapsed and refractory B-cell non-Hodgkin lymphoma1. Per the terms of the agreement, AstraZeneca will make an upfront payment of $100 million upon the closure of the deal. In addition to the upfront payment, the existing shareholders of TeneoTwo will also be eligible to receive contingent R&D-related milestone payments of up to $805 million and additional contingent commercial-related milestone payments of up to $360 million.
FDA’s Priority Tag to Roche’s Lymphoma Candidate BLA: The FDA accepted and granted priority review to Roche’s biologics license application (BLA) for Lunsumio, to treat adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior systemic therapies. Lunsumio is a potential first-in-classCD20xCD3 T-cell engaging bispecific antibody. The FDA is expected to give its decision on the BLA by Dec 29, 2022. The BLA is based on positive results from the pivotal phase I/II GO29781 study.
Pfizer Files NDA for Paxlovid: Pfizer announced that it has filed a new drug application (NDA) to seek formal approval from the FDA for its oral COVID-19 antiviral pill, Paxlovid. Paxlovid was granted Emergency Use Authorization (EUA) in the United States in December 2021 for the treatment of mild-to-moderate COVID-19 in patients who are at high risk of progression to severe COVID-19. The NDA seeks approval of Paxlovid for patients who are at high risk for progression to severe illness from COVID-19. The NDA was based on data from the phase II/III EPIC-HR study. Paxlovid has already received emergency or conditional authorization for use in certain populations in more than 65 countries.
The NYSE ARCA Pharmaceutical Index rose 0.63% in the last five trading sessions.
Here’s how the eight major stocks performed in the last five trading sessions.
Image Source: Zacks Investment Research
In the last five trading sessions, Merck rose the most (2%) while AbbVie declined the most (0.8%).
In the past six months, Lilly rose the most (26.1%) while Roche declined the most (17.5%).
(See the last pharma stock roundup here: FDA Panel Backs Updated COVID Jabs, EU Nod for SNY, MRK Drugs)
What's Next in the Pharma World?
Watch for regular pipeline and regulatory updates next week.